3.238.204.31
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Nephrology
Trending Topics

Combination Therapy Demonstrates Clinically Meaningful Efficacy in RCC

Posted on April 20, 2021
Case Report: Goodpasture Syndrome and Hemorrhage After Renal Biopsy

Data from a Phase 3 clinical trial (CheckMate -9ER) evaluating cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) compare to sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma significantly improved progression-free survival, according to a press release.

Secondary endpoints of overall survival (OS) at a pre-specified interim analysis and objective response rate (ORR) were also met.

“We are delighted that this pivotal CheckMate -9ER trial met its key efficacy measures of progression-free survival as well as overall survival for previously untreated kidney cancer patients, with a favorable safety profile. These positive topline results support the growing body of data that shows Cabometyx may create a more immune-permissive tumor environment that could enhance the response to immune checkpoint inhibitors,” said Dr. Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen in apress release. “We look forward to discussing these results with global health authorities with the aim to bring this new combination regimen to previously untreated kidney cancer patients, a population that, despite recent advances, remains in need of additional therapeutic options that extend survival.”

Read the press release here.

Source: Ipsen

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-